Independent since Jun 2012
Quality Professional
Lydall Jun 2010 - May 2012
Quality Manager
Johnson Controls 1999 - 2009
Quality Manager
Troy Mills Inc 1982 - 1998
Corporate Director of Quality
Education:
University of Maine
Skills:
Automotive Six Sigma Quality Assurance Quality Management Quality System Project Management Continuous Improvement Engineering Manufacturing Program Management Lean Manufacturing FMEA Kaizen Root Cause Analysis Management Supplier Quality 5S SPC Process Improvement Kanban ISO Engineering Management TQM
Interests:
Quality Management, Continuous Quality Improvement and Photography
Name / Title
Company / Classification
Phones & Addresses
Thomas Boucher Principal
Event Production Services Services-Misc
561 Boylston St, Boston, MA 02116
Thomas J Boucher Secretary
ALL STAR RACING ASSOCIATION, INC
1592 State St, Springfield, MA 01109 1 Ross Cir, Assonet, MA 02702
Thomas F. Boucher Treasurer
RAMELLI FORD SALES, INC
124 N Main St, Uxbridge, MA 01569 105 N Main St, Uxbridge, MA
Thomas C. Boucher Manager
GREEN MOUNTAIN ENERGY PARTNERS LLC
Edward L Selgrade, Lexington, MA 02173 Fuller Mt Rd North Ferrisburg Vt 05473-0000 Usa<Br/>Fuller Mt Rd North Ferrisburg, North Ferrisburgh, VT 05473
- Emeryville CA, US Thomas Francis Boucher - Boston MA, US Roman Yelensky - Newton MA, US
International Classification:
G16B 40/00
Abstract:
A method for identifying neoantigens that are likely to be presented on a surface of tumor cells of a subject. Peptide sequences of tumor neoantigens are obtained by sequencing the tumor cells of the subject. The peptide sequence of each of the neoantigens is associated with one or more k-mer blocks of a plurality of k-mer blocks of the nucleotide sequencing data of the subject; The peptide sequences and the associated k-mer blocks are input into a machine-learned presentation model to generate presentation likelihoods for the tumor neoantigens, each presentation likelihood representing the likelihood that a neoantigen is presented by an MHC allele on the surfaces of the tumor cells of the subject. A subset of the neoantigens is selected based on the presentation likelihoods.